Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. 



Frontline tislelizumab plus chemotherapy significantly improved progression-free survival compared with chemotherapy alone in patients with non-squamous non-small cell lung cancer (NSCLC), according to phase III data.



Patients with previously untreated stage IIIB or stage IV non-squamous NSCLC without EGFR or ALK translocations. 



Patients were randomized 2:1 to receive tislelizumab 200 mg every three weeks combined with pemetrexed 500 mg/m2 and investigator’s choice of platinum chemotherapy or pemetrexed and platinum chemotherapy alone.







Leave a Reply

Your email address will not be published.